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Abstract
Background: The pulmonary microcirculation is the chief regulatory site for resistance in the pulmonary circuit. Despite
pulmonary microvascular dysfunction being implicated in the pathogenesis of several pulmonary vascular conditions, there
are currently no techniques for the specific assessment of pulmonary microvascular integrity in humans. Peak hyperemic
flow assessment using thermodilution-derived mean transit-time (Tmn) facilitate accurate coronary microcirculatory
evaluation, but remain unvalidated in the lung circulation. Using a high primate model, we aimed to explore the use of Tmn
as a surrogate of pulmonary blood flow for the purpose of measuring the novel indices Pulmonary Flow Reserve
[PFR=(maximum hyperemic)/(basal flow)] and Pulmonary Index of Microcirculatory Resistance [PIMR=(maximum hyperemic
distal pulmonary artery pressure)6(maximum hyperemic Tmn)]. Ultimately, we aimed to investigate the effect of progressive
pulmonary microvascular obstruction on PFR and PIMR.
Methods and Results: Temperature- and pressure-sensor guidewires (TPSG) were placed in segmental pulmonary arteries
(SPA) of 13 baboons and intravascular temperature measured. Tmn and hemodynamics were recorded at rest and following
intra-SPA administration of the vasodilator agents adenosine (10–400 mg/kg/min) and papaverine (3–24 mg). Temperature
did not vary with intra-SPA sensor position (0.01060.009 v 0.01060.009uC; distal v proximal; p=0.1), supporting Tmn use in
lung for the purpose of hemodynamic indices derivation. Adenosine (to 200 mg/kg/min) & papaverine (to 24 mg) induced
dose-dependent flow augmentations (4067% & 35613% Tmn reductions v baseline, respectively; p,0.0001). PFR and PIMR
were then calculated before and after progressive administration of ceramic microspheres into the SPA. Cumulative
microsphere doses progressively reduced PFR (1.4160.06, 1.2660.19, 1.1760.07 & 1.0160.03; for 0, 10
4,1 0
5 &1 0
6
microspheres; p=0.009) and increased PIMR (5.760.6, 6.361.0, 6.860.6 & 7.660.6 mmHg.sec; p=0.0048).
Conclusions: Thermodilution-derived mean transit time can be accurately and reproducibly measured in the pulmonary
circulation using TPSG. Mean transit time-derived PFR and PIMR can be assessed using a TPSG and adenosine or papaverine
as hyperemic agents. These novel indices detect progressive pulmonary microvascular obstruction and thus have with a
potential role for pulmonary microcirculatory assessment in humans.
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Introduction
The pulmonary microvasculature is the principal site regulating
resistance, and thus pressure, in the pulmonary circulation[1].
Diseases of the pulmonary microcirculation, such as pulmonary
vascular disease (PVD)[2] and chronic thromboemobolic pulmo-
nary hypertension (CTEPH)[3], are characterized by progressive
microvascular obstruction[2,3], presenting with markedly elevated
pulmonary artery pressures (PAP)[4,5] and thus portending poor
prognosis[5,6]. Currently under recognized[5,7], both PVD and
CTEPH rely on pressure-based diagnostic modalities for detection
(eg. echocardiography and right heart catheterization[8]), which
are inherently insensitive to the initial pulmonary microvascular
losses that precede PAP rise. A more direct assessment of
pulmonary microcirculatory status may potentially facilitate
improved detection of such conditions.
Advances in miniaturized sensor guidewire technology have
enabled the use of both Doppler flow velocity[9] and thermodi-
lution-derived mean transit-time (Tmn)[10] for assessment of the
coronary circulation in ischemic heart disease. The index of
coronary flow reserve (CFR = maximum hyperemic divided by basal
coronary blood flow) aims to evaluate coronary lesion hemodynamic
significance by recruiting all available vascular reserves and
expressing maximum resultant flow as a multiple of basal flow.
Although capable of detecting microvascular obstruction[11],
CFR is not specific to the coronary microcirculation, denoting the
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9601combined extent of both epicardial and coronary micrvascular
disease in the territory assessed[12]. The recently described index
of microcirculatory resistance[13] (IMR = maximum hyperemic distal
coronary artery pressure times maximum hyperemic Tmn) has been proven
to be more microcirculation-specific[14], reproducible[15] and
independent of systemic hemodynamics[15] than CFR, tracking
true microcirculatory resistance[13]. In contrast, there are
currently no established techniques for evaluating the pulmonary
microcirculation in vivo, a unique vascular bed characterized by
low arterial pressure, high vessel compliance and close proximity
to alveolar air.
We previously described the use of Doppler flow velocity in
hemodynamic assessment of the pulmonary circulation[16] and
thus utilized this technology to recently validate and measure
pulmonary flow reserve (PFR = maximum hyperemic divided by basal
pulmonary blood flow) in healthy baboons[17]. The use of
temperature and pressure sensor-guidewire (TPSG) technology
(which facilitates simultaneous thermodilution-derived flow and
pressure recordings thus enabling concurrent CFR and IMR
evaluations in the coronary circulation[15]), however, has not
been described in the pulmonary circulation. We hypothesized
that: 1) PFR and a novel pulmonary index of microcirculatory
resistance (PIMR = maximum hyperemic distal PAP times maximum
hyperemic mean transit-time) could be measured accurately using a
TPSG and; 2) that these novel flow and resistance indices may
allow the detection of microvascular obstruction. We thus utilized
a high-primate model of invasive pulmonary hemodynamic
assessment[17] in order to: 1) demonstrate the feasibility of
thermodilution-derived mean transit-time (Tmn)-based pulmonary
blood flow assessments using a TPSG and; 2) demonstrate the
feasibility and reproducibility of measuring a PFR and PIMR
using a TPSG. Ultimately, we aimed to, for the first time, study the
effect of progressive, experimentally induced microcirculatory
obstruction on these novel pulmonary indices of resistance and
flow. Our results demonstrate that both PFR and PIMR can
detect progressive, partial obstruction of the pulmonary microcir-
culation, with potential implications for the improved detection of
pulmonary microvascular disease.
Methods
(See a more detailed description of pre-, intra- and post-
procedural animal care in Methods S1 and its accompanying
Figure S1):
Ethics Statement
The study was conducted in accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes (7th Edition, 2004) and the National Health and
Medical Research Council Policy on the Care and Use of Non-
Human Primates for Scientific Purposes. The study was
approved by the Sydney South Western Area Health Service
Animal Ethics Committee (EasternZ o n e ) .A l la s p e c t so fa n i m a l
care prior to, during and following the study procedures outlined
below were overseen by the veterinary team of the Australian
National Baboon Colony. Any untoward events were monitored
for and managed using established animal welfare and behavior
protocols. Two procedures were abandoned prematurely, one
due to in situ thrombus formation within the distal segmental
pulmonary artery being studied and the other due to limited
radio-contrast agent extravasation within the lung. All animals
returned to normal function within 24 hours, with minimal signs
of distress or discomfort. Finally, in keeping with the ethical
principles of Replacement, Reduction and Refinement with
relation to the use of non-human primates in medical research,
experiments were only repeated until statistically meaningful
results were observed. Thus, different groups of animals were
utilized for different aspects of the below-described research
protocol.
Animal Model and Preparation
Thirteen healthy baboons (Papio hamadryas; weight 19.961.3 kg)
were chosen for the species’ anatomic and hemodynamic similarity
to humans. We used a modification of our previously described
methods for invasive pulmonary hemodynamic assessments in
higher primates[17], as seen in Figure 1. In brief, following
ketamine anesthesia, bilateral femoral venous access was estab-
lished. A 7F multipurpose (MP) 55 cm guiding catheter was placed
at the ostium of a left lower lobe segmental pulmonary artery and
a 5F 100 cm MP guide positioned just proximal. Femoral arterial
access allowed for continuous systemic hemodynamic monitoring.
Following heparin (50–100 U/kg) administration, a 0.0140 TPSG
(PressureWire-5 or PressureWire-Certus, Radi Medical Systems,
Uppsala, Sweden) was inserted via the 7F-MP, advanced to the
distal third of the segmental pulmonary artery of interest and
connected to its dedicated monitoring console (Radi Analyzer-X,
Radi Medical Systems, Uppsala, Sweden). Finally, we note that all
aspects of animal care were delivered by a dedicated veterinary
team and all animals recovered uneventfully.
Control Measurements
Constant intravascular temperature is a prerequisite for
thermodilution-derived assessments of flow. We thus recorded
distal, mid and proximal segmental pulmonary artery tempera-
tures in triplicates, using a TPSG pullback maneuver, after
calibrating the TPSG to an arbitrary zero reference point within
the left main pulmonary artery (n=4).
TPSG-Derived Mean Transit Time for the Assessment of
Flow
The TPSG utilized in our study consists of a distal temperature
and pressure sensor mounted on an electrically conductive shaft
capable of acting as a proximal second thermistor. Fundamentally,
Figure 1. Experimental setup: Using femoral vascular access, a 7F
multipurpose (MP) guiding catheter was placed in a left lower lobe
segmental pulmonary artery (PA). A 5F-MP was placed alongside the 7F-
MP and positioned proximal to it. A temperature and pressure sensor
guidewire (TPSG) was passed through the 7F-MP and placed within the
distal PA.
doi:10.1371/journal.pone.0009601.g001
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relating flow (Q), intravascular volume sampled (V) and mean
transit-time (Tmn) required for blood to traverse the sample
space[10]:
Q~
V
Tmn
ðEquation 1Þ
The use of TPSG for Tmn-based assessment of flow was
initially described in an in vitro system, validated against
absolute flow in the canine coronary circulation[10] and then
validated in the human coronary circulation[18]. In examining
the utility of Tmn in the primate pulmonary circulation, we have
therefore carefully adapted methods originally described above,
in accordance with the literature and with our previous
pulmonary vascular physiology studies in high primates[17].
In particular, TPSG-derived Tmn was defined (and automati-
cally computed by the RadiAnalyzer-X console; Radi Medical
Systems, Uppsala, Sweden) by expressing the distally-sensed
thermodilution curve inscribed by room-temperature saline
bolus-injection as a function of the time elapsed from the
saline’s arrival at the wire’s proximal thermistor, using the
following equation:
Tmn~
Ð ?
0 t:ct ðÞ dt Ð ?
0 ct ðÞ dt
where t is time and c is temperature ðÞ ½ 10 
ðEquation 2Þ
Thermodilution-derived mean transit-time assessments have
been shown to be independent of indicator volume and
temperature, provided that the amount utilized does not in itself
alter underlying flow and adequate indicator-blood mixing
occurs[10]. Thus, 3 mL room temperature saline boluses were
deemed optimal for Tmn-based assessment of coronary blood flow
using a 6F catheter[10]. Given that indicator boluses in our study
were to be administered via a larger 7F multipurpose catheter
(internal volume 3 mL) and that our previous baboon work
demonstrated no change in segmental pulmonary artery flow with
saline boluses up to 10 mL in volume, we chose a 3.5 mL bolus for
Tmn-based assessment of pulmonary blood flow. Thorough
flushing of the catheter with room temperature saline prior to
each triplicate Tmn recordings ensured that subsequent indicator
boluses were of even temperature[19] allowing for use of
minimum bolus volume and promoting adequate indicator-blood
mixing. As thermodilution calculations are automatically gated to
the indicator’s arrival at the proximal TPSG thermistor (defined as
a rate of temperature change greater than 23.3uC per second at
this sensor) the time required to fill the catheter with saline can, by
definition, be ignored. Of interest, the distal temperature sensor
must detect a magnitude of change greater than 1uC in order to
calculate Tmn.
The distance between the tip of the 7F-MP and the distal TPSG
tip was kept .6 cm at all times, in keeping with previous
validation work which demonstrated that distances .6 cm were
associated with significantly less Tmn variability than distances
,5 cm[10], likely due to improved indicator-blood mixing.
Finally, in keeping with work in the coronary circulation[10]
and in order to quantify the variability of Tmn measurements in the
pulmonary circulation, we recorded Tmn in triplicate for each
hemodynamic loading condition in each animal.
Defining Maximal Pulmonary Hyperemia
Attainment of maximal pulmonary hyperemia is fundamental to
reproducible PFR and PIMR assessments. The following vasodi-
lators were administered directly into the segmental pulmonary
artery of 4 animals, in order of increasing duration of action: 1)
adenosine (1 mg/mL) infusions at 10, 100, 200 and 400 mg/kg/
min, for 2–3 mins each, and; 2) papaverine (3 mg/mL) boluses of
3, 6, 12, 24 and 48 mg every 2–4 mins. These agents were chosen
as they have been previously demonstrated to elicit microvascular
hyperemia in the pulmonary[17] and coronary beds[20,21].
Systemic arterial pressures (as recorded by the femoral arterial
pressure monitor), pulmonary arterial pressures (as sensed at the
tip of the 7F-MP and recorded as peak mean PAP during a
respiratory cycle, thus coinciding with expiration)[22], heart rate
(as recorded from the continuous electrocardiography or systemic
arterial pressure monitor) and Tmn were obtained at baseline and
at maximal steady-state (90–120 secs into infusions, 30–90 secs
after boluses).
Thermodilution-Derived Measurements of PFR Using
TPSG
Thermodilution-derived assessment of blood flow are based
upon the indicator-dilution theory relating flow (Q), intravascular
volume sampled (V) and mean transit-time (Tmn) required for blood
to traverse the sample space[10], as noted in Equation 1.
By definition,
PFR~
Qmaximal hyperemia
Qbasal
ðEquation 3Þ
Therefore:
PFR~
Vmax hyperemia
Tmn max hyperemia
|
Tmn basal
Vbasal
ðEquation 4Þ
As maximal adenosine- and papaverine-induced pulmonary
hyperemia occurs in the absence of change in conduit vessel
diameter in the baboon[17], Vmax hyperemia = Vbasal. Thus, using
either agent to induce hyperemia, thermodilution-derived PFR
(PFRthermo) can be expressed as:
PFRthermo~
Tmn basal
Tmn max hyperemia
ðEquation 5Þ
Using TPSG to measure Tmn and either adenosine 200 mg/kg/
min or papaverine 24 mg to induce maximal pulmonary
hyperemia[17], we thus measured PFRthermo in the intact
pulmonary microvasculature of 11 baboons.
Thermodilution-Derived Measurements of PIMR Using
TPSG
The relationship between flow, pressure (P) and resistance (R),
obeys Ohm’s law:
R~
P
Q
ðEquation 6Þ
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R~
P|Tmn
V
ðEquation 7Þ
A TPSG can provide simultaneous pressure and thermodilu-
tion-derived Tmn recordings. While exact resistance calculations
require knowledge of arterial volume, resistance estimates can be
made using a TPSG only, by calculating a resistance index (RI):
RI~P|Tmn ðEquation 8Þ
Measurement of the resistance index during maximum microcir-
culatory hyperemia (when, in theory, all available microvessels have
been recruited) provides an estimate of minimum achievable
microvascular resistance. Moreover, by recording pressure and Tmn
distally, the potential effect a hemodynamically significant
proximal artery stenosis may have on this estimate can be
mitigated. Thus, the pulmonary index of microvascular resistance
(PIMR) is defined as follows:
PIMR~Pdistal pulmonary artery|Tmn ðEquation 9Þ
Using TPSG to measure Tmn and the maximum hyperemic
doses of either adenosine or papaverine to induce maximal
pulmonary hyperemia, we thus measured PIMR in the intact
pulmonary microvasculature of 10 animals.
Effect of Cumulative Microvascular Obstruction on
PFRthermo and PIMR
After establishing the feasibility of measuring PFRthermo and
PIMR measurements using TPSG, increasing amounts of ceramic
microspheres (10
4,1 0
5 and 10
6 particles; diameter 40–120 mm;
Embospheres, Biosphere Medical, Rockland, MA) were adminis-
tered into the segmental artery of 7 baboons. Microsphere sizes
were chosen to obstruct the same caliber vessels as affected by
human PVD (,100 mm)[2], noting that .99.8% of 50 mm
diameter microspheres lodge in the baboon pulmonary circula-
tion[23]. Baseline and maximal adenosine-induced hyperemic
hemodynamics were recorded 60secs after each microsphere
bolus.
Statistical Analysis
All data are presented as mean6SEM. Analysis was performed
using either Prism 4 software (GraphPad Software, San Diego,
California, USA) or the SAS System for Windows version 9 (SAS
Institute, Cary, North Carolina, USA). Two-way ANOVA with
repeated measures was used for comparisons (unless otherwise
stated) with 2-tailed p-values ,0.05 regarded significant. Vari-
ability within a set of measures was calculated using the coefficient
of variability. For microsphere experiments, linear mixed models
were fitted to test for trend in dose response thus allowing for
differing number of observations made between animals and for
repeated measures within each animal.
Results
Effect of Sensor Position on Intravascular Temperature
The measurement of flow using indicator thermodilution
method assumes a constant basal temperature within the vessel
studied, attributing any change in temperature to the indicator per
se. This assumption remains unproven in the pulmonary
circulation, where blood vessels are in close proximity to air.
Using a TPSG pullback maneuver, we found no temperature
gradient across the segmental pulmonary artery interrogated
(0.01060.009, 0.00560.015 and 0.01060.009uC for distal, mid
and proximal segmental pulmonary artery positions, p=0.1).
Therefore, Tmn can be used as a surrogate marker of pulmonary
blood flow in the higher primate model.
Effect of Adenosine on Tmn, Hemodynamics and Cardiac
Rhythm
Adenosine has an established role as coronary hyperemic
agent[20] and was recently shown to induce pulmonary hyperemia
for Doppler sensor guidewire-based PFR assessments in higher
primates[17]. Increasing adenosine infusion rates produced
significant, dose-dependent reductions in Tmn (0.3860.07,
0.3660.05, 0.2860.01, 0.2360.03 and 0.2460.02sec for baseline,
10, 100, 200 and 400 mg/kg/min, p,0.0001; maximal effect at
200 mg/kg/min equivalent to 4067% reduction in Tmn v baseline;
Figure 2). Concurrently, adenosine induced systemic hypotension
(10768, 102610, 100610, 8465 and 7864 mmHg for baseline,
100, 200 and 400 mg/kg/min, p=0.0009), without affecting heart
rate (9366, 9269, 9568, 9766 and 9864 beats-per-minute for
baseline, 10, 100, 200 and 400 mg/kg/min, p=0.4) or mean PAP
(1261, 1061, 1364 and 1663 mmHg for baseline, 100, 200 and
400 mg/kg/min, p=0.3). These findings are consistent with
published adenosine pharmacodynamics[17,20].
Effect of Papaverine on Tmn, Hemodynamics and Cardiac
Rhythm
Papaverine is a known coronary hyperemic agent[21] and was
recently shown to safely effect pulmonary hyperemia in higher
primates[17]. Increasing papaverine boluses induced dose-depen-
dent reductions in Tmn (0.3960.06, 0.3360.04, 0.2760.06,
0.2860.07 and 0.2560.05 sec for baseline, 3, 6, 12 and 24 mg,
p,0.0001; maximal Tmn reductions of 35613% v baseline;
Figure 3). Doses above 24 mg (up to 48 mg) were poorly tolerated
due to rapid hemodynamic shifts, resulting in disruption of
experimental setup. In addition to its effect on Tmn, papaverine
Figure 2. Adenosine induces dose-dependent reductions in
Tmn, plateauing at $200 mg/kg/min: Tmn – thermodilution-derived
mean transit time; error bars represent SEM.
doi:10.1371/journal.pone.0009601.g002
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10466 beats-per-minute for baseline, 3, 6, 12 and 24 mg,
p,0.0001) without affecting mean systemic pressure (10669,
105612, 107611, 98612 and 104612 mmHg for baseline, 3, 6,
12 and 24 mg, p=0.4) or mean PAP (1961, 1962, 1962, 2063
and 2063 mmHg for baseline, 3, 6, 12 and 24 mg, p=1.0). These
hemodynamic effects are consistent with previously published data
for papaverine[17,24].
Variability of Tmn Measurements
The variability of Tmn measurements was 10.561.8% and
15.662.7% at baseline and during maximal hyperemia, respectively.
PFRthermo in Healthy Primates
PFRthermo values in the intact pulmonary microvasculature were
calculated (Equation 5) to be 1.5560.12 and 1.5460.12 using
adenosine and papaverine, respectively (p=0.8 using paired t-test
for complementing data sets, comparing both agents).
PIMR in Healthy Primates
To study the effect of pulmonary hyperemia on pulmonary
microvascular resistance estimates, we compared baseline, distally-
measured resistance indices (RIbasal) (Equation 8) with PIMR
(measured at hyperemia; Equation 9). Overall, there was a
statistically significant drop in microvascular resistance at maximal
hyperemia (7.860.7 vs 5.460.4 mmHg.sec for RIbasal vs PIMR,
p,0.0001, two-tailed paired t-test). More specifically, the
reduction in resistance estimates was similar for adenosine-induced
hyperemia (7.861 vs 5.460.6 mmHg.sec, RIbasal vs PIMR,
p=0.003, two-tailed paired t-test) and papaverine-induced
hyperemia (7.760.6 vs 5.460.6 mmHg.sec, RIbasal vs papaver-
ine-derived PIMR, p=0.006, two-tailed paired t-test).
Effect of Progressive Microcirculatory Obstruction on
Thermodilution Derived Pulmonary Hemodynamic
Indices
To study the effect of progressive microcirculatory obstruction
on PFRthermo and PIMR, increasing numbers of microspheres were
administered into the segmental pulmonary artery. Index
calculations were repeated after each bolus, using adenosine to
induce hyperemia.
Cumulative microsphere administration progressively reduced
PFRthermo (1.4160.06, 1.2660.19, 1.1760.07 and 1.0160.03 for
baseline, 10
4,1 0
5 and 10
6 microspheres bolus, p=0.009, Figure 4).
Additionally, progressive microvascular obstruction using mi-
crospheres led to a progressive rise in PIMR (5.760.6, 6.361.0,
6.860.6 and 7.660.6 mmHg.sec for baseline, 10
4,1 0
5 and 10
6
microspheres bolus, p=0.0048, Figure 5). These changes occurred
in the absence of microsphere effect on resting heart rate (9665,
9666, 9565 and 9666 beats-per-minute for baseline, 10
4,1 0
5
and 10
6 microspheres bolus, p=0.14), mean systemic artery
pressure (11064, 11664, 10666 and 10766 mmHg, p=0.12) or
mean distal segmental PAP both at maximal hyperemia (2362,
2262, 2262, 2162 mmHg, p=0.43) and at baseline (2062,
2261, 2162 and 2062 mmHg, p=0.85).
Figure 3. Papaverine induces dose-dependent increases in Tmn:
Tmn – thermodilution-derived mean transit time; error bars represent
SEM.
doi:10.1371/journal.pone.0009601.g003
Figure 4. Cumulative microvascular obstruction induces pro-
gressive reductions in PFRthermo: PFRthermo – thermodilution-derived
pulmonary flow reserve. The theoretical minimum value of PFR=1 is
noted by a dashed line as reference; error bars represent SEM.
doi:10.1371/journal.pone.0009601.g004
Figure 5. PIMR tracks progressive pulmonary microvascular
obstruction: PIMR – pulmonary index of microcirculatory resistance;
error bars represent SEM.
doi:10.1371/journal.pone.0009601.g005
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The salient findings of our study in high primates are: 1) that no
significant intravascular temperature gradient exists along seg-
mental pulmonary artery, permitting the use of thermodilution-
based assessment of mean transit time for pulmonary blood flow
evaluation in high primates; 2) that reproducible thermodilution-
derived pulmonary flow reserve and pulmonary index of micro-
circulatory resistance assessments can be performed in the
pulmonary circuit using either intrapulmonary adenosine or
papaverine as hyperemic agents and; 3) that progressive
pulmonary microvascular obstruction, of an extent insufficient to
affect systemic hemodynamics or pulmonary artery pressure,
results in progressive reductions in pulmonary flow reserve and
elevations in pulmonary index of microcirculatory resistance.
These findings suggest that both pulmonary flow reserve and
pulmonary index of microcirculatory resistance may have clinical
utility for improving detection of pulmonary microvascular
disease.
There is increasing evidence implicating pulmonary microcir-
culatory dysfunction as the key pathogenetic process underlying
pulmonary vascular disease[2] and chronic thromboembolic
pulmonary hypertension[3]. These insidious conditions tend to
present late, manifesting clinically only when the pulmonary artery
pressure has risen[4] and thus portending a poor prognosis[5,6].
The inherent insensitivity of current pressure-based diagnostic
techniques for early microvascular loss and the promise of
improved prognosis with early intervention[25] both provide an
emergent clinical impetus for improved recognition of pulmonary
microvascular dysfunction.
Measuring Pulmonary Flow and Defining Maximal
Pulmonary Hyperemia Using Thermodilution
We have recently demonstrated that PFR can be measured
using a Doppler-flow velocity sensing guidewire in a higher
primate model, using either adenosine 200 mg/kg/min or
papaverine 24 mg to induce maximal hyperemia[17]. While
Doppler-sensor guidewires measure flow velocity only[9], TPSG
technology offers simultaneous assessment of pressure and
thermodilution-derived flow[10], thus facilitating more compre-
hensive hemodynamic evaluations. Although utilized extensively
in the coronary circulation[10,18], TPSG use has not been
validated in the pulmonary circuit. We demonstrate for the first
time that despite the pulmonary circulation’s close proximity to
air, there is no temperature gradient along the pulmonary artery,
supporting the use of thermodilution as a surrogate marker of
pulmonary blood flow in this model for the purpose of pulmonary
hemodynamic indices derivation. We demonstrate that reproduc-
ible Tmn measurements can be made in the pulmonary circulation
of higher primates but note that our reported variability between
triplicate Tmn, measures, however, was somewhat greater than the
variability of Doppler flow velocity noted in our Doppler-derived
PFR study[17]. Respiratory, and to a lesser degree, cardiac cycle-
dependent variations in pulmonary blood flow were likely major
contributors to Tmn variability in the current study, with the
discontinuous nature of Tmn recording disallowing sufficient
sampling rate frequency for cycle phase-specific gating of Tmn
measurement (as opposed to continuous Doppler flow velocity
recordings). We postulate however, that the random distribution of
Tmn variability makes it unlikely to invalidate our findings (which
reflect the sum of numerous recordings in multiple animals) and
note that studies which validated Tmn against absolute coronary
blood flow[10] reported a similar Tmn variability to that seen in our
pulmonary work.
With regards to pulmonary hyperemia, our study demonstrates
that maximal adenosine induced-flow augmentations (seen as
reductions in Tmn) occur at infusions rate of 200 mg/kg/min with
equivalent increments in flow induced by papaverine 24 mg.
These findings, and the magnitudes of flow augmentation seen at
hyperemia, are similar to those noted in the Doppler PFR
studies[17], suggesting reasonable correlation between Doppler
flow-velocity (vdopp) and Tmn, and supporting the robustness of our
higher primate model. Of interest, although adenosine infusions
induced the expected systemic hypotension in our study, reflex
tachycardia was not seen. This finding has been previously noted
in healthy humans[26] yet is seemingly at odds with our previous
experience with adenosine use in baboons[17] and with other
reports of adenosine use in humans[20,27], but we suspect that it is
likely a statistical phenomenon relating to the small sample size
rather than a true physiologic finding.
Thermodilution-Derived PFR Assessment in Higher
Primates
Assessments of flow reserve seek to quantify the magnitude of
maximum recruitable vascular reserves through the ratio of
maximum hyperemic to baseline blood flow. Although coronary
flow reserve evaluations have been performed using either
Doppler flow-velocity or thermodilution-derived mean transit-
time as surrogate measures of flow, Tmn-based CFR has proven to
correlate better with CFR derived from absolute flow[11]. We
recently demonstrated that Doppler-derived PFR can be measured
in the pulmonary circulation of higher primates[17] and thus
sought to assess the feasibility of Tmn-based PFR assessment in a
similar model, before studying the relationship between PFRthermo
and progressive microvascular obstruction.
To reproducibly measure PFR using Tmn (Equation 3) we
ensured that baseline measurement were made only once all
parameters returned to the basal state and performed hyperemic
measurements at steady state for adenosine or at peak effect for
papaverine. As adenosine- and papaverine-induced pulmonary
hyperemia in the baboon does not affect conduit vessel
diameter[17], PFRthermo can be calculated using Tmn only, without
the need for calculating intravascular volume (Equation 4). We
thus demonstrated that in the baboon intact pulmonary
microvasculature, both adenosine- and papaverine-derived
PFRthermo is approximately 1.5, in keeping with our recently
published Doppler-derived PFR measures[17].
PIMR Assessment in Higher Primates
IMR evaluations of the coronary circulation seek to quantify
microvascular integrity by estimating minimum achievable microvascu-
lar resistance, a related measure to maximal vascular flow reserve
assessment with CFR. By incorporating simultaneous distal
coronary artery pressure and flow recordings at peak hyperemia
only (as measured by a single sensor guidewire), IMR allows for
more specific evaluation of the coronary microcirculation than
CFR[15]. Moreover, IMR assessments have been shown to
correlate with true microvascular resistance[13] and with clinical
outcomes after myocardial infarction[28]. Our current findings
demonstrate that reproducible PIMR measurements can be made
in the baboon pulmonary circulation using either adenosine or
papaverine as hyperemic agents, yielding a value of approximately
5.5 mmHg.sec in the intact lung microvasculature.
PFRthermo and PIMR Detect Microvascular Obstruction
After assessing PFRthermo and PIMR in the intact microvascu-
lature, we studied the ability of these novel indices to detect
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delivery of microspheres. We chose adenosine to induce
pulmonary hyperemia for these serial hemodynamic evaluations,
as its infusions provided more predictable steady-states and returns
to baseline when compared to papaverine boluses. We found that
increasing doses of microspheres, of a size known to obstruct the
baboon pulmonary microvasculature[23], resulted in progressive
reduction in PFRthermo mirrored by increases in PIMR, without
affecting heart rate, mean systemic artery pressure or mean PAP.
These results indicate that both PFRthermo and PIMR are capable of
detecting partial pulmonary microvascular obstruction.
Our study does not compare the respective sensitivity of
PFRthermo and PIMR for the detection of microvascular obstruc-
tion. We expect, however, that by obviating the need for repeated
baseline assessments, PIMR may prove more reproducible than
PFRthermo. Moreover, as coronary IMR is a more independent of
epicardial arterial stenoses than CFR[15], we suspect that PIMR
may be more specific to the pulmonary microcirculation than
PFRthermo.
Potential Clinical Implications
PFRthermo and PIMR evaluations, or variations thereof, may
potentially assist in the diagnostic workup of patients suspected of
having conditions such as PVD or CTEPH who are mildly
symptomatic, have normal PAP yet manifest an otherwise
unexplained reduced gas-transfer function (a crude indicator of
available pulmonary microvascular reserve). Such evaluations may
identify disease either by returning a single ‘lower than expected’
PFRthermo or ‘higher than expected’ PIMR value, or by demon-
strating progressive change upon serial testing. With specific
reference to CTEPH, the measurement of our proposed
physiologic indices may potentially provide an improved appre-
ciation of the extent of underlying microcirculatory dysfunction
driving the disease[3] when compared to the more proximal
pulmonary vessel evaluation of multi-detector computer tomo-
gram pulmonary angiography and the qualitative evaluation of the
ventilation and perfusion scan. Whether our proposed methods
are superior to established diagnostic techniques remains the
subject of future human studies.
Study Limitations
We acknowledge that pulmonary microvascular obstruction
using microspheres is not a validated model of pulmonary
microvascular disease in humans. Our use of microspheres was
aimed at simulating increases in pulmonary vascular resistance,
the common pathway for pathophysiologic mechanisms underly-
ing conditions such as PVD[29]. In keeping with this proof-of-
concept study design, we also restricted our choice of hyperemic
stimuli to those most commonly employed for in vivo assessment of
the microcirculation, namely, adenosine and papaverine. Howev-
er, our study cannot determine the relative contribution that either
arterial or venous dilatation has made on hyperemia-induced
increases in pulmonary blood flow. Nevertheless, previous work by
Bhattacharya et al[1] in the pulmonary circulation of anesthetised
dogs demonstrated that: 1) there was no measureable resistance
proximal to the 50 mm arterioles or distal to the 20 mm venules
and; 2) that 61% of total pulmonary vascular resistance lies
proximal to the mid capillary point. These findings, along with our
previous observations that maximal pulmonary hyperemic doses of
both adenosine and papaverine do not affect the diameter of the
segmental pulmonary arteries of baboons[17], support the notion
that the proximal pulmonary microvasculature (arterioles to
capillaries) is the major site of action of these hyperemic agents
in the pulmonary circulation.
As is inherent in the inverse-square relationship between PAP
and microvascular cross sectional area, limited microvascular
obstruction experiments in a single lung segment will not
increase resting PAP. Moreover, as the rest of the pulmonary
circuit in our model was left intact, local resistance increases in
the obstructed segment would have shunted blood flow to
unaffected lung and its reserves, maintaining steady resting
pressure throughout. Our experiments therefore cannot com-
pare the sensitivities of our pulmonary hemodynamic indices
versus PAP with regards to detection of microvascular obstruc-
tion as ethical considerations precluded microsphere adminis-
tration bilaterally to the entire pulmonary circulation, leaving
this question to be answered in future studies of human
pulmonary microvascular disease. Interestingly, however, while
microspheres reduced PFR and increased PIMR, mean PAP at
peak hyperemia (where, in theory, no further blood redistribu-
tion can occur) did not change, supporting the possibility that
these measures may be more sensitive than PAP for detecting
microvascular obstruction.
Due to the complexity and length of the study protocol we were
unable to measure cardiac output (CO) or pulmonary capillary
wedge pressure (PCWP) and explore the effect of pharmacolog-
ically-induced hyperemia on CO and PCWP and the potential
‘flow-on’ effect on PFR and PIMR. Regarding hyperemia and
CO, we acknowledge that the decrements in Tmn seen during
adenosine-induced hyperemia may, in part, be due to the drug’s
known ability to augment CO[26]. However, the PFR reductions
and PIMR increases observed in the microsphere experiments are
likely due to changes in the microvasculature rather than to
reductions in cardiac output as: 1) they occurred following partial
obstruction of a small portion of the pulmonary microvasculature
(flow persisted even following maximal microsphere dose) and; 2)
the microspheres did not affect heart rate, systemic or pulmonary
artery pressure. These observations support our hypothesis that
these indices detect variations in hyperemia-recruited microvas-
cular reserves, though more definitive proof is required from
subsequent human studies. With regards to potential hyperemia-
induced changes in PCWP and their effect on physiologic index
derivation, we recognize that such changes may proportionally
have a greater effect on the transpulmonary pressure gradient than
changes in systemic venous pressures would have on the gradient
across the higher-pressured systemic circulation. Nevertheless, our
current work demonstrates a relationship between PFR or PIMR
and progressive microcirculatory disruption. This observation is
further strengthened by an apparent inverse relationship between
PIMR and PFR per se during microsphere administration.
The magnitude of maximal hyperemia in our model was only
modest, inducing 50% augmentation in flow, equal to a PFR of
1.5. Given that pulmonary blood flow represents the entire cardiac
output (CO), PFR, in theory, should be equal to the ratio of
maximum attainable to baseline cardiac outputs in the animals
studied. Moreover, as humans can increase CO during exercise at
least 4-fold[30], we expect the normal high primate PFR to be of
similar magnitude. Despite these considerations, the thermodilu-
tion-derived PFR values observed are consistent with our
previously reported studies of Doppler-derived PFR in higher
primates[17]. These lower-than-expected values may be species
specific but are more likely a function of ketamine’s known ability
to depress cardiac output in vasodilated animals[31] while
opposing nitric oxide dependent vasodilatation[32] (and thus
limiting maximum vessel recruitment). However, even within the
confines of this narrowed response range, PFRthermo was capable of
detecting subtle degrees of microvascular obstruction, supporting
our primary study hypothesis.
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obtaining stable and complete experimental setup in the smaller
upper lobes of the baboons, our studies were confined to the left
lower lobes of all animals. With flow in the lung traditionally
divided into West zones on account of gravity-dependent
variations in arterial opening pressures[33], it is possible that
PFR may be different for the upper and lower lobes. However,
with gravity shown to account for only 7% of pulmonary blood
flow heterogeneity in the supine primate[34], PFR may potentially
be less lobe-dependent in our healthy baboon model. This issue
remains to be resolved in future studies, especially in the setting of
pulmonary vascular disease where marked interlobar variability of
pulmonary artery remodeling is seen[35].
Finally, due to the discontinuous nature of Tmn recordings we
could not account for the potential effect of cardiac and respiratory
cycle-dependent variations in vessel diameter and flow on our Tmn-
derived pulmonary physiologic indices. The baboons’ relatively
fast heart rates and uncontrolled, spontaneous breathing further
precluded such assessments. That said, we presume that the rapid,
cardiac cycle-dependent undulations in flow would result in
random Tmn measurement error and thus have less influence on
our observations as a whole. The fact that Tmn has been shown to
correlate strongly with absolute blood flow in the coronary
circulation[10], where the cardiac cycle would presumably have a
similar effect on vessel diameter, further supports this argument.
With regards to the known effect of respiration on hemodynamics,
we mitigated mean PAP sampling error by only recording peak
mean PAP during each respiratory cycle (occurring at peak
expiration in the spontaneously breathing animal)[22]. We
propose, in fact, that respiratory-dependent changes in Tmn likely
contributed, at least in part, to the larger variability of triplicate
Tmn recordings (10.5%) when compared to that of continuously-
sampled, respiratory cycle-gated Doppler flow velocity (3.3%) in
the baboon’s pulmonary circulation (3.3%)[17]. The similarity
between thermodilution and Doppler derived PFR however
suggests that overall, the effect of respiration on Tmn-derived flow
indices may be lessened by repeated sampling.
Conclusion
Diagnostic techniques for the detection of pulmonary micro-
vascular abnormalities are lacking. We demonstrate that safe and
reproducible assessment pulmonary flow reserve and pulmonary
index of microcirculatory resistance can be performed in a primate
model, using a temperature and pressure sensor guidewire and
either adenosine or papaverine as hyperemic agents. Moreover,
we show that these indices track progressive pulmonary micro-
vascular obstruction. Although suggestive of potential clinical use,
further studies are required to validate and evaluate the utility of
these novel indices of pulmonary microvascular status in humans.
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Figure S1 Experimental setup: Using femoral vascular access, a
7F multipurpose (MP) guiding catheter was placed in a left lower
lobe segmental pulmonary artery (PA). A 5F-MP was placed
alongside the 7F-MP and positioned proximal to it. A temperature
and pressure sensor guidewire (TPSG) was passed through the 7F-
MP and placed within the distal PA.
Found at: doi:10.1371/journal.pone.0009601.s002 (0.16 MB TIF)
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